Brainstorm Cell Therapeutics Raises $10.5M In Non-Public Offering

June 18, 2014 | Israeli biotechnology company Brainstorm Cell Therapeutics announced that it raised $10.5 million in private placement, or a non-public offering. The funds from the offering will go towards the phase II clinical trials for an ALS (Lou Gehrig’s disease) treatment that the company has developed. Brainstorm Cell’s treatment is called NurOwn for both ALS, Multiple Sclerosis and Parkinson’s disease, but now the company is considering examining its use for the treatment of autism.